0422: Efficacy and Safety of Secukinumab in the Treatment of Axial Spondyloarthritis: Real-Life Data from TURKBIO Cohort

Semih Gulle¹, Ali Karakas¹, Gercek Can², Soner Senel³, Sedat Capar⁴, Huseyin ediz dalkilic⁵, Servet Akar⁶, Suleyman Serdar Koca⁷, Abdurrahman Tufan⁸, Ayten Yazici⁹, Sema Yilmaz¹⁰, Nevsun Inanc¹¹, Merih Birlik¹, Dilek Solmaz¹², Ayse Cefle⁹, Berna Goker¹³, Servet Yolbas¹⁴, Niels Steen Krough¹⁵, Neslihan Yilmaz¹⁶, Sukran Erten¹⁷, Cemal Bes¹⁸, Ozgul Soysal¹⁹, Mehmet Akif Ozturk¹³, Seminur Haznedaroglu¹³, Sule Yavuz¹⁶, Haner Direskeneli²⁰, Fatoş Onen²¹ and Ismail Sari²², ¹Dokuz Eylul University School of Medicine Division of Rheumatology, Izmir, Turkey, ²Dokuz Eylul University School of Medicine Division of Rheumatology, Istanbul, Turkey, ³Erciyes University School of Medicine Division of Rheumatology, Kayseri, Turkey, ⁴Dokuz Eylul University Faculty of Science Department of Statistics, Izmir, Turkey, ⁵Uludag University School of Medicine Division of Rheumatology, Bursa, Turkey, ⁶Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ⁷Firat University School of Medicine Division of Rheumatology, Elazıg, Turkey, ⁸Gazi University Medical Faculty Hospital, Istanbul, Turkey, ⁹Kocaeli University School of Medicine Division of Rheumatology, Kocaeli, Turkey, ¹⁰Selcuk University School of Medicine Division of Rheumatology, Konya, Turkey, ¹¹Marmara University School of Medicine, Division of Rheumatology, Istanbul, Turkey, ¹²Kâtip Celebi University School of Medicine Division of Rheumatology, Izmir, Turkey, ¹³Gazi University School of Medicine Division of Rheumatology, Ankara, Turkey, ¹⁴Inonu University School of Medicine Division of Rheumatology, Malatya, Turkey, ¹⁵Zitelab Aps, Kopenhag, Denmark, ¹⁶Demiroglu Bilim University School of Medicine Division of Rheumatology, Istanbul, Turkey, ¹⁷Yildirim Beyazit University School of Medicine Division of Rheumatology, Ankara, Turkey, ¹⁸Basaksehir Cam and Sakura ospital, Division of Rheumatology, Istanbul, Turkey, ¹⁹Celal Bayar University, School of Medicine Division of Rheumatology, Manisa, Turkey, ²⁰Marmara University School of Medicine Division of Rheumatology, Istanbul, Turkey, ²¹Dokuz Eylul University, Faculty of Medicine, Rheumatology, İzmir, Turkey, ²²Dokuz Eylul University School of Medicine Division of Rheumatology, İzmir, Turkey

Background/Purpose: In this study, we aimed to evaluate the results of secukinumab treatment in patients with Axial Spondyloarthritis (AxSpA) who were enrolled in the TURKBIO cohort.

Methods: In our study, AxSpA patients registered in the TUKRBIO database were evaluated. 6, 12 and 24 months of secukinumab drug retention, inactive disease/low disease activity (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] < 2/< 4, Ankylosing Spondylitis Disease Activity Score [ASDAS] < 1.3/< 2.1) and response rates (BASDAI50, Spondyloarthritis International Society [ASAS] 20/40, ASDAS clinically significant improvement [ASDAS-CII] and ASDAS major improvement [ASDAS-MI]) were evaluated.

Results: Follow-up data of 184 AS patients registered in the TURKBIO registry were evaluated. Of these patients, 52 (28.3%) were bDMARD naive patients and 132 (71.7) had used at least one bDMARD prior to secukinumab. Age and gender distribution were similar between bDMARD naive and ≥1 bDMARD groups. At 1-year follow-up, 60 and 12 patients discontinued their treatment in the ≥1 bDMARD group and the secukinumab group, respectively (p< 0.001). Ineffectiveness was the most common reason for discontinuing treatment in the ≥1 bDMARD and secukinumab groups. The rate of continuation of secukinumab treatment was 71.7% at 6 months and 60.9% at 12 months. When clinical conditions were assessed based on prior bDMARD use, there were significantly better drug survival rates at 6 months and 12 months for the bDMARD naive group (82.7% and 76.9 months, respectively). In addition, it was determined that the symptoms and the time elapsed after diagnosis did not affect the efficacy of secukinumab. In our study, no significant drug safety problem was encountered in the follow-up of secukinumab treatment for more than 3 years.

Conclusion: In a study conducted with TURKBIO real-life data, we found that secukinumab treatment in patients with AxSpA had better clinical response and higher drug survival rates in biologically naive patients, similar to TNFi treatment. However, it has been observed that the use of secukinumab in the second or subsequent steps in patients who do not respond to biologics has similar success rates to TNFi treatment results.Table 1 Demographic and clinical characteristics of AxSpA patients

Graphic 1. Secukinumab 3-year drug retention
Disclosures: S. Gulle, None; A. Karakas, None; G. Can, None; S. Senel, None; S. Capar, None; H. dalkilic, None; S. Akar, AbbVie, Lilly, MSD, Novartis, Pfizer, UCB; S. Koca, None; A. Tufan, None; A. Yazici, None; S. Yilmaz, None; N. Inanc, AbbVie/Abbott, Eli Lilly, Merck/MSD, novartis, Pfizer, Roche, Amgen, Celltrion, UCB; M. Birlik, None; D. Solmaz, None; A. Cefle, None; B. Goker, None; S. Yolbas, None; N. Krough, None; N. Yilmaz, None; S. Erten, None; C. Bes, None; O. Soysal, None; M. Ozturk, None; S. Haznedaroglu, None; S. Yavuz, None; H. Direskeneli, None; F. Onen, None; I. Sari, None.